Jaguar Health announced that the U.S. Food and Drug Administration has approved renewal of Canalevia-CA1. Canalevia-CA1, the company’s conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea in dogs, is available from multiple veterinary distributors in the U.S., including Chewy. The renewal for conditional approval is in effect until December 21, 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JAGX:
- Jaguar Health says top line results for Phase 3 OnTarget trial ‘forthcoming’
- Jaguar Animal Health Inc. (JAGX) Q3 Earnings Cheat Sheet
- Jaguar Health’s Napo to present results of quality of life survey
- Jaguar Health receives additional 180-day grace period to regain compliance
- Jaguar Health enters license, commercialization agreement with Quadri Pharma